» Articles » PMID: 24508386

Effects of Growth Hormone Administration for 6 Months on Bone Turnover and Bone Marrow Fat in Obese Premenopausal Women

Overview
Journal Bone
Date 2014 Feb 11
PMID 24508386
Citations 21
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: Abdominal adiposity is associated with low BMD and decreased growth hormone (GH) secretion, an important regulator of bone homeostasis. The purpose of our study was to determine the effects of a short course of GH on markers of bone turnover and bone marrow fat in premenopausal women with abdominal adiposity.

Materials And Methods: In a 6-month, randomized, double-blind, placebo-controlled trial we studied 79 abdominally obese premenopausal women (21-45 y) who underwent daily sc injections of GH vs. placebo. Main outcome measures were body composition by DXA and CT, bone marrow fat by proton MR spectroscopy, P1NP, CTX, 25(OH)D, hsCRP, undercarboxylated osteocalcin (ucOC), preadipocyte factor 1 (Pref 1), apolipoprotein B (ApoB), and IGF-1.

Results: GH increased IGF-1, P1NP, 25(OH)D, ucOC, bone marrow fat and lean mass, and decreased abdominal fat, hsCRP, and ApoB compared with placebo (p<0.05). There was a trend toward an increase in CTX and Pref-1. Among all participants, a 6-month increase in IGF-1 correlated with 6-month increase in P1NP (p=0.0005), suggesting that subjects with the greatest increases in IGF-1 experienced the greatest increases in bone formation. A six-month decrease in abdominal fat, hsCRP, and ApoB inversely predicted 6-month change in P1NP, and 6-month increase in lean mass and 25(OH)D positively predicted 6-month change in P1NP (p≤0.05), suggesting that subjects with greatest decreases in abdominal fat, inflammation and ApoB, and the greatest increases in lean mass and 25(OH)D experienced the greatest increases in bone formation. A six-month increase in bone marrow fat correlated with 6-month increase in P1NP (trend), suggesting that subjects with the greatest increases in bone formation experienced the greatest increases in bone marrow fat. Forward stepwise regression analysis indicated that increase in lean mass and decrease in abdominal fat were positive predictors of P1NP. When IGF-1 was added to the model, it became the only predictor of P1NP.

Conclusion: GH replacement in abdominally obese premenopausal women for 6 months increased bone turnover and bone marrow fat. Reductions in abdominal fat, and inflammation, and increases in IGF-1, lean mass and vitamin D were associated with increased bone formation. The increase in bone marrow fat may reflect changes in energy demand from increased bone turnover.

Citing Articles

Function and Regulation of Bone Marrow Adipose Tissue in Health and Disease: State of the Field and Clinical Considerations.

Zhang X, Tian L, Majumdar A, Scheller E Compr Physiol. 2024; 14(3):5521-5579.

PMID: 39109972 PMC: 11725182. DOI: 10.1002/cphy.c230016.


Quantitative assessment of lumbar spine bone marrow in patients with different severity of CKD by IDEAL-IQ magnetic resonance sequence.

Xiong Y, He T, Liu W, Zhang Y, Hu S, Wen D Front Endocrinol (Lausanne). 2022; 13:980576.

PMID: 36204094 PMC: 9530399. DOI: 10.3389/fendo.2022.980576.


Bone marrow adipose tissue in metabolic health.

Pachon-Pena G, Bredella M Trends Endocrinol Metab. 2022; 33(6):401-408.

PMID: 35396163 PMC: 9098665. DOI: 10.1016/j.tem.2022.03.003.


Impact of GH administration on skeletal endpoints in adults with overweight/obesity.

Dichtel L, Haines M, Gerweck A, Bollinger B, Kimball A, Schoenfeld D Eur J Endocrinol. 2022; 186(6):619-629.

PMID: 35315344 PMC: 9400128. DOI: 10.1530/EJE-21-1061.


Cross-sectional associations between adipose tissue depots and areal bone mineral density in the UK Biobank imaging study.

Bland V, Klimentidis Y, Bea J, Roe D, Funk J, Going S Osteoporos Int. 2021; 33(2):391-402.

PMID: 34490505 DOI: 10.1007/s00198-021-06140-w.


References
1.
James W, Caterson I, Coutinho W, Finer N, Van Gaal L, Maggioni A . Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N Engl J Med. 2010; 363(10):905-17. DOI: 10.1056/NEJMoa1003114. View

2.
Abdallah B, Ding M, Jensen C, Ditzel N, Flyvbjerg A, Jensen T . Dlk1/FA1 is a novel endocrine regulator of bone and fat mass and its serum level is modulated by growth hormone. Endocrinology. 2007; 148(7):3111-21. DOI: 10.1210/en.2007-0171. View

3.
Compston J, Watts N, Chapurlat R, Cooper C, Boonen S, Greenspan S . Obesity is not protective against fracture in postmenopausal women: GLOW. Am J Med. 2011; 124(11):1043-50. PMC: 4897773. DOI: 10.1016/j.amjmed.2011.06.013. View

4.
Baum H, Biller B, Finkelstein J, Cannistraro K, Oppenhein D, Schoenfeld D . Effects of physiologic growth hormone therapy on bone density and body composition in patients with adult-onset growth hormone deficiency. A randomized, placebo-controlled trial. Ann Intern Med. 1996; 125(11):883-90. DOI: 10.7326/0003-4819-125-11-199612010-00003. View

5.
Koh J, Khang Y, Jung C, Bae S, Kim D, Chung Y . Higher circulating hsCRP levels are associated with lower bone mineral density in healthy pre- and postmenopausal women: evidence for a link between systemic inflammation and osteoporosis. Osteoporos Int. 2005; 16(10):1263-71. DOI: 10.1007/s00198-005-1840-5. View